Position of the Transparency Council – Impavido (miltefosine)

At its meeting on 12 September 2022 the Transparency Council adopted position No. 89/2022 on on the legitimacy of granting consent for reimbursement of the medicinal product  Impavido (miltefosine) for the indication: visceral leishmaniasis (ICD-10: B55.0) in the course of human immunodeficiency virus (HIV) infection.

Publication in Public Information Bulletin (BIP)